Avita Medical logo

AVH - Avita Medical Share Price

A$0.69 -0.0  -2.8%

Last Trade - 24/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £673.7m
Enterprise Value £658.6m
Revenue £4.26m
Position in Universe 231st / 1828
Bullish
Bearish
Unlock AVH Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AVH Revenue Unlock AVH Revenue

Net Income

AVH Net Income Unlock AVH Revenue

Normalised EPS

AVH Normalised EPS Unlock AVH Revenue

PE Ratio Range

AVH PE Ratio Range Unlock AVH Revenue

Dividend Yield Range

AVH Dividend Yield Range Unlock AVH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AVH EPS Forecasts Unlock AVH Revenue
Profile Summary

Avita Medical Limited is a medical technology company. The principal activities of the Company are the commercialization of its regenerative product. The Company has three segments: the Asia Pacific region; the Americas, including Canada, and the Europe, Middle East and Africa (EMEA) region. It develops and distributes regenerative products for the treatment of a range of wounds, scars and skin defects. Its collection and application technology provides treatment solutions derived from the regenerative properties of a patient's own skin. The Company's product, ReCell, is used in the treatment of a range of burns, plastic, reconstructive and cosmetic procedures. Its technology, Regenerative Epithelial Suspension (RES), is an autologous suspension composed of the cells and wound-healing factors necessary to regenerate natural skin. The Company also offers ReGenerCell, which is used for the treatment of wounds, and ReNovaCell, which is used for the treatment of pigmentation.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated December 21, 1992
Public Since August 11, 1993
No. of Shareholders: n/a
No. of Employees: 87
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,871,299,575
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AVH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AVH
Upcoming Events for AVH
Similar to AVH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.